$0.52
0.00%Key Stats | |
---|---|
Open | $0.52 |
Prev. Close | $0.54 |
EPS | -1.37 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $8.32M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.52 | 0.56 |
52 Week Range | 0.50 | 2.05 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.37 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo